|
| Press Releases |
|
 |
|
| Tuesday, April 5, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
|
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options |
| Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"). more info >> |
|
| Tuesday, March 29, 2016 |
|
|
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan |
| Eisai Co., Ltd. announced today that its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) has been approved in Japan as an adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs. more info >> |
|
| Tuesday, March 22, 2016 |
|
|
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
| Thursday, March 17, 2016 |
|
|
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym |
| Eisai Co., Ltd. announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. has been informed the results of deliberation of the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council's meeting held on March 17 regarding the egg white lysozyme preparation Neuzym (lysozyme hydrochloride, "lysozyme") which had been submitted for reevaluation. more info >> |
|
| Monday, February 15, 2016 |
|
|
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the Field of Dementia |
| Eisai Co., Ltd. and Sysmex Corporation jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia. more info >> |
|
| Friday, February 12, 2016 |
|
|
Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet |
| Eisai Co., Ltd. announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma)[1] have been published in the online version of The Lancet. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Honda Unveils Next-generation Technologies at "Honda Automotive Technology Workshop" for Electrified Models to be Launched in Second Half of 2020s
Nov 6, 2025 22:44 JST
|
|
|
Market Value Lower Than Cash Assets? It's Time to Reevaluate NIVF 
Nov 6, 2025 21:36 HKT/SGT
|
|
|
Winvest Group Announces Strategic Partnership with Greater Bay Area RWA Incubator; Southeast Asia Headquarters to Be Established in Malaysia
Nov 6, 2025 21:30 HKT/SGT
|
|
|
K.Wah Group Supports 2025 Legislative Council Election
Nov 6, 2025 21:09 HKT/SGT
|
|
|
Ten organizations have jointly launched a project titled "Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry"
Nov 6, 2025 22:00 JST
|
|
|
Fujitsu to develop new chatbot for Japan Pension Service
Nov 6, 2025 21:24 JST
|
|
|
The 17th Hong Kong International Wine & Spirits Fair Opens Today
Nov 6, 2025 19:16 HKT/SGT
|
|
|
Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
Nov 6, 2025 17:30 JST
|
|
|
Excent Capital Announces Swap-Free Trading on All U.S. Stocks and Indices
Nov 6, 2025 16:00 HKT/SGT
|
|
|
ESA, MediaTek, Eutelsat, Airbus, Sharp, ITRI, and R&S Announce World's First Rel-19 5G-Advanced NR-NTN Connection over OneWeb LEO Satellites
Nov 6, 2025 17:00 JST
|
|
|
Hybrid Dump Truck Demonstration Test at South African Mining Site Selected by UNIDO's Industrial Cooperation Programme
Nov 6, 2025 16:16 JST
|
|
|
Mitsubishi Power Receives Contract to Upgrade Existing Boiler Equipment at the O Mon 1 Thermal Power Plant in Vietnam
Nov 6, 2025 16:01 JST
|
|
|
Tune Talk partners with Truecaller to Enhance Customer Experience and Trust Across Malaysia's Telecom Sector
Nov 6, 2025 15:00 HKT/SGT
|
|
|
MHI and ICM Form Strategic Alliance to Advance Ethanol Dehydration Efficiency
Nov 6, 2025 15:38 JST
|
|
|
Telecoms World Asia 2025 Returns To Bangkok to Power Asia's Connected Future
Nov 6, 2025 14:33 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
